Background-Acyclovir (ACV) ophthalmic ointment is effective in the treatment ofherpetic keratitis. However, when applied, the ointment has an unpleasant feeling and some cases are resistant to ACV. A new antiviral compound, carbocyclic oxetanocin G (C.OXT-G) has potent anti-herpes simplex virus activity and high water solubility, so the clinical effect of C.OXT-G eyedrops on ulcerative herpetic keratitis was evaluated. Methods-Studies were conducted on the corneal ulcers in 37 eyes of 27 patients. Patients with typical dendritic or geographic corneal ulcers were treated with 0/1% C.OXT-G eyedrops, applied five times a day, together with eyedrops of an antibiotic applied four times a day. The eyes were examined at least twice a week until the ulcers healed, and thereafter at intervals for up to 3 months. Results-All of the ulcers healed, their average healing time being 4 9 (SD 2.2) (range 2 to 9) days. The ulcers in 20 of the 37 eyes were induced by the use of corticosteroid or immunosuppressive drugs, and their average healing time was 4*8 (2.3) days. No adverse drug reactions were seen during the observation period in this trial. Conclusion-Eyedrops containing 0./1% C.OXT-G are excellent and safe for treatment of herpes simplex corneal ulcers in humans.
0/1% C.OXT-G eyedrops, applied five times a day, together with eyedrops of an antibiotic applied four times a day. The eyes were examined at least twice a week until the ulcers healed, and thereafter at intervals for up to 3 months. Results-All of the ulcers healed, their average healing time being 4 9 (SD 2.2) (range 2 to 9) days. The ulcers in 20 of the 37 eyes were induced by the use of corticosteroid or immunosuppressive drugs, and their average healing time was 4*8 (2.3) days. No adverse drug reactions were seen during the observation period in this trial. Conclusion-Eyedrops containing 0./1% C.OXT-G are excellent and safe for treatment of herpes simplex corneal ulcers in humans. (BrJ Ophthalmol 1996; 80: [413] [414] [415] but the ointment has an unpleasant feeling when applied. Therefore, we have been searching for new anti-herpes simplex virus (HSV) drugs that are soluble in water and have potent anti-HSV activity.
Carbocyclic oxetanocin G (C.OXT-G) is a new antiviral compound in which guanine is attached to a cyclobutane ring (Fig 1) . I It is active against not only HSV, 1-13 but also other viruses including varicella zoster virus,11 13 cytomegalovirus,11-3 Epstein Barr virus,13 and human immunodeficiency virus.13 14 Shiota, Nitta, Naito, Mimura, Maruyama dendritic or geographic ulcers. Also when possible, a very small part of the ulcer edge was scraped off and a fluorescent antibody test against HSV was made for confirmation of the diagnosis. Informed consent was obtained from all patients included in this study. Treatment was carried out on an outpatient basis. Eyedrops of 0-1% C.OXT-G, which was synthesised by one of the authors (TM), were made by dissolving the compound in physiological saline without a preservative and sterilising the solution of pH 6-6 by filtration. Patients were told to apply exactly one drop (0051 ml) of 0/1% C.OXT-G eyedrop solution five times a day during the time when they were awake. In addition, they were told to apply one drop of antibiotic eyedrop solution, usually 03% ofloxacin, four times a day to prevent secondary bacterial infection. If the patients were suffering from iritis at the start of this study, they also applied a drop of 1% atropine eyedrop solution once a day. The patients were advised not to apply other eyedrops at the same time. If the patients were using steroid eyedrops and stromal involvement was not seen or was minimal, they stopped applying the steroid drops and followed the above treatment schedule during this trial. However, if the patients were using steroid eyedrops and stromal involvement or iritis was prominent, they were weaned off by decreasing the steroid concentration in a way such as that described by McGill and others19 during the above treatment schedule. If the patients were taking immunosuppressive drugs systemically because of other diseases, they continued their use in addition to applying the above topical treatment during the trial.
The patients' eyes were examined at least twice a week using a photo slit-lamp after staining with fluorescein until the ulcers had healed, then once every 7 days for 1 month, and 1 and 2 months later. Thus they were followed up for 3 months after the disappearance of ulcers. The end point of ulcer healing was judged by the same criterion as that used by othersl 8 20; namely, we judged ulcers as healed when specific fluorescein staining of the sites of the ulcers disappeared. We disregarded fine microscopic punctate stainings of the epithelial surface, if any, when judging the healing time. C.OXT-G eyedrops were applied five times a day until 1 week after the ulcers had healed. Application of the drops was then stopped, or continued three times a day for another week if there was still a granular appearance at the sites of previous ulcers.
At each visit to hospital, the patients were examined by more than one ophthalmologist to obtain consistent agreement on whether ulcers had healed, and photographs were taken with a Zeiss photo slit-lamp. The cornea, the lids, and the conjunctiva were all examined for possible adverse drug reactions during the whole observation period.
Results
Studies were made on the corneal ulcers in 37 eyes of 27 patients (14 male, 13 female; average age 56-9 years). All these ulcers healed, their average healing time being 4 9 (SD 2.2) days (range 2 to 9 days). Of the 37 eyes, 32 had dendritic ulcers whose average healing time was 4-7 (2.1) days, while the other five had geographic ulcers which showed an average healing time of 6-2 (2 3) days. The ulcers in 20 eyes of 11 patients were induced by the use of corticosteroid eyedrops (10 eyes) or systemic immunosuppressive drugs (10 eyes). However, the ulcers in these eyes all healed with an average healing time of 4-8 (2-3) days. One of the 11 patients was a man aged 58 years on his initial visit who had had a kidney transplantation and had to take immunosuppressive drugs, mainly cyclosporin A. He had suffered from ulcerative herpetic keratitis nine times in the past 3 years. However, his corneal ulcers were always healed by 0-1% C.OXT-G eyedrops. The average healing time of ulcers in this patient was 5-2 (2-3) days. Our results are summarised in Table 1 . No adverse drug reactions were seen during the observation period in this trial. Discussion IDU and ACV are the only drugs commercially available in Japan for the treatment of herpetic keratitis. ACV has a better therapeutic effect,68 less toxicity,9 and better penetration into the anterior chamber'0 than IDU, so use of ACV ophthalmic ointment is now the treatment of choice in Japan. However, the ointment has an unpleasant feel and some cases are resistant to ACV.21-24 The anti-HSV drugs ara-A4 and F3T5 are also effective for the treatment of herpetic keratitis. But ara-A must be used as an ointment, which also has an unpleasant feel when applied, and for various reasons, no pharmaceutical companies market F3T eyedrops in Japan. Therefore, new anti-HSV drugs with strong anti-HSV activity and high water solubility are required for preparation of effective eyedrops.
We found in previous studies that C.OXT-G is a possible candidate, because 0-1% C.OXT-G eyedrops applied 10 times a day exhibited an excellent therapeutic effect in the treatment of herpetic keratitis in rabbits. '8 Moreover, no toxic effects of C.OXT-G eyedrops were detected during these animal experiments, and after application of 0-1% C.OXT-G eyedrops five times a day for 3 months to six normal rabbits, the corneas did not show any abnormalities on slit-lamp or histopathological examination.
Based on these findings of the efficacy and safety of 0-1% C.OXT-G eyedrops against herpetic keratitis in rabbits, in the present clinical trial, 0-1% C.OXT-G eyedrops were applied five times a day to typical herpes simplex corneal ulcers. Results showed that 0.10% C.OXT-G eyedrops were very effective for the treatment of herpes simplex comeal ulcers in humans. Our preliminary results with the smaller number of seven eyes were reported in Japanese elsewhere,'8 and to the best of our knowledge, this is the first report in English of a large scale study showing the efficacy of C.OXT-G against herpetic keratitis in humans. The ulcers in 20 eyes were induced by the use of steroid eyedrops or systemic immunosuppressive drugs, but all healed on treatment with C.OXT-G eyedrops. Thus 
